MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company
28 mai 2020 14h11 HE
|
MatriSys Bioscience
SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by...
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors
26 mai 2020 12h25 HE
|
MatriSys Bioscience
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors
19 mai 2020 03h09 HE
|
MatriSys Bioscience
SAN DIEGO, May 19, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
20 mars 2019 19h55 HE
|
MatriSys Bioscience
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...
MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors
11 mars 2019 03h11 HE
|
MatriSys Bioscience
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
03 janv. 2019 03h01 HE
|
MatriSys Bioscience
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has...
MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors
12 nov. 2018 04h11 HE
|
MatriSys Bioscience
SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis
21 août 2017 06h00 HE
|
MatriSys Bioscience
SAN DIEGO, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the first patient...
MatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis
22 févr. 2017 17h39 HE
|
MatriSys Bioscience
SAN DIEGO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience (MatriSys Bio) is pleased to announce the publication of breakthrough scientific results from the laboratory of Dr. Richard Gallo at...